Aqneursa (levacetylleucine)

Ataxia-telangiectasia

Also known as IB1001

Manufacturer: IntraBio
Regulatory submission: sNDA submitted March 2026 and approved September 2026
Launch: Commercially available at approval in September 2026
Last updated: October 2, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

52 evidence topics · 29 sources

Multidisciplinary supportive care5 evidence topics · 5 sources
Physical, occupational, and speech therapy5 evidence topics · 5 sources
Symptomatic medications for ataxia and movement disorders10 evidence topics · 10 sources
Corticosteroids12 evidence topics · 12 sources
Immunoglobulin replacement and infection prophylaxis4 evidence topics · 4 sources
Respiratory care6 evidence topics · 5 sources
Nutritional support and gastrostomy6 evidence topics · 8 sources
Limitations of current therapies4 evidence topics · 16 sources